NCT02736617View on ClinicalTrials.gov

Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

July 5, 2016

Primary Completion Date

June 2, 2021

Study Completion Date

June 2, 2021

Conditions

Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma

Interventions

DRUG

Ibrutinib

Given PO

BIOLOGICAL

Obinutuzumab

Given IV

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER